Otelixizumab

Phase 3Monoclonal antibody

GSK

Otelixizumab is one of 113 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Type 1 DiabetesActive, not recruiting

Thyroid Eye DiseaseActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Thyroid Eye DiseasePhase 2

Active, not recruiting

Type 1 Diabetes MellitusPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Otelixizumab

GSK

Phase 3

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Simponi

Johnson & Johnson

Preclinical

19 5

Ilaris

Novartis

Preclinical

3 6

Celexa

AbbVie

Preclinical

1 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 9

Rituxan

Pfizer

Preclinical

7 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus3 trials

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Completed· GSK logo

GSK·Phase 3·NCT01123083·179 enrolled

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Completed· GSK logo

GSK·Phase 1/2·NCT02000817·30 enrolled

Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus

Terminated· GSK logo

GSK·Phase 2·NCT01222078·1 enrolled

Thyroid Eye Disease1 trial

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

Terminated· GSK logo

GSK·Phase 2·NCT01114503·2 enrolled

Type 1 Diabetes1 trial

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Terminated· GSK logo

GSK·Phase 2·NCT00451321·88 enrolled

T1DM1 trial

Subcutaneous Administration of Otelixizumab to T1DM Patients

Completed· GSK logo

GSK·Phase 1·NCT00946257·33 enrolled

Rheumatoid Arthritis1 trial

Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis

Terminated· GSK logo

GSK·Phase 1·NCT01077531·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Otelixizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Otelixizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Otelixizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: GSK

Otelixizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes Mellitus3 trials

Thyroid Eye Disease1 trial

Type 1 Diabetes1 trial

T1DM1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News